The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer-Reference-Cited by-同舟云学术

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer

Published:2020-05-06 Issue:13 Volume:9 Page:4603-4612
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Goldstein Daniel A.¹²³^ORCID,Mayer Chen⁴,Shochat Tzippy⁵,Reinhorn Daniel¹²,Moore Assaf¹²^ORCID,Sarfaty Michal¹²,Yerushalmi Rinat¹²,Goldvaser Hadar¹²^ORCID

Affiliation:

1. Davidoff Cancer Center Beilinson HospitalRabin Medical Center Petach‐Tikva Israel

2. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

3. Department of Health Policy and Management Gillings School of Global Public HealthUniversity of North Carolina at Chapel Hill Chapel Hill NC USA

4. Department of Pathology Sheba Medical Center Ramat Gan Israel

5. Statistical Consulting Unit Beilinson HospitalRabin Medical Center Petach‐Tikva Israel

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3088

Reference32 articles.

1. Breast cancer statistics, 2017, racial disparity in mortality by state

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

3. Breast Cancer Subtypes and the Risk of Local and Regional Relapse

4. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

5. Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center;Pathology and Oncology Research;2024-04-16

2. Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2− breast cancer: a retrospective cohort study;World Journal of Surgical Oncology;2022-10-12

3. The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer;Cancer Reports;2021-10-19